219 related articles for article (PubMed ID: 30111379)
1. Rectal perforation following paclitaxel and carboplatin chemotherapy for advanced ovarian cancer: a case report and review of the literature.
Jayakody S; Wright DB; Chiong C; Liu M; Bouffler C; El-Khoury T
J Med Case Rep; 2018 Aug; 12(1):221. PubMed ID: 30111379
[TBL] [Abstract][Full Text] [Related]
2. A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Carter J; Durfee J
Gynecol Oncol; 2007 Dec; 107(3):586-9. PubMed ID: 17949798
[TBL] [Abstract][Full Text] [Related]
3. A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
Zhou X; Hu P; Yue Y; Duan Z
Eur J Gynaecol Oncol; 2012; 33(5):540-2. PubMed ID: 23185808
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
Abaid LN; Lopez KL; Micha JP; Rettenmaier MA; Brown JV; Goldstein BH
Eur J Gynaecol Oncol; 2010; 31(3):308-11. PubMed ID: 21077475
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
[TBL] [Abstract][Full Text] [Related]
6. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.
Gadducci A; Gargini A; Palla E; Fanucchi A; Genazzani AR
Anticancer Res; 2005; 25(3c):2509-13. PubMed ID: 16080485
[TBL] [Abstract][Full Text] [Related]
7. [A case of multiple intestinal perforation secondary to paclitaxel and carboplatin combined chemotherapy for lung cancer].
Liu ZC; Wu D; Lan SJ; Wang DD
Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):399-400. PubMed ID: 31137178
[No Abstract] [Full Text] [Related]
8. Syndrome of inappropriate secretion of anti-diuretic hormone following carboplatin-paclitaxel administration in a patient with recurrent ovarian cancer.
Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Eur J Gynaecol Oncol; 2005; 26(5):531-2. PubMed ID: 16285572
[TBL] [Abstract][Full Text] [Related]
9. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
Ebata T; Yunokawa M; Bun S; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
11. Acute pancreatitis induced by paclitaxel and carboplatin therapy in an ovarian cancer patient.
Shintani D; Yoshida H; Imai Y; Fujiwara K
Eur J Gynaecol Oncol; 2016; 37(2):286-7. PubMed ID: 27172765
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
14. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Vergote I; Amant F; Oskay-Oezcelik G; Musib L; Michel AL; Darstein C; Kania M; Bauknecht T; Sehouli J
Int J Gynecol Cancer; 2009 Dec; 19(9):1505-10. PubMed ID: 19955926
[TBL] [Abstract][Full Text] [Related]
17. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
18. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
20. Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer.
Ozguroglu M; Sari O; Turna H
Int J Gynecol Cancer; 2006; 16 Suppl 1():394-6. PubMed ID: 16515631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
